FEED earnings analysis
What we found in FEED's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not contain the interim income statement, balance sheet, cash-flow statement, segment data, or quantitative operating outlook, so revenue, margins, EPS, cash, debt, working-capital, and free-cash-flow trends cannot be assessed from the filing text supplied. The filing does disclose that controls remained ineffective as of June 30, 2026 and that the company faces substantial Nasdaq listing risk tied to a bid price below $1.00 and the EnVue transaction. Financing activity also involved $7,600 of preferred-stock proceeds and conversion of $7,719 of stated value plus $602 of dividends into 6,049,233 common shares, indicating continued reliance on equity financing and material dilution.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Series H financing generated $7,600
- The company issued 7,600 shares of Series H Preferred Stock during the six months ended June 30, 2026, generating aggregate gross proceeds of $7,600; 3,700 shares generating $3,700 were issued in the second quarter.
- Preferred conversions drove heavy dilution
- Alpha converted $7,719 of Series H stated value plus $602 of accrued dividends into 6,049,233 common shares during the six months ended June 30, 2026. Second-quarter conversions totaled $2,917 of stated value and $151 of accrued dividends into 3,448,738 common shares.
- Material weakness remediation underway
- Management reported remediation efforts involving revised controls, documentation, monitoring, and inventory-system training, with assistance from a third-party finance and accounting provider. However, management stated that not all material weaknesses may be remediated after these efforts.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Internal controls remain ineffective
- As of June 30, 2026, the CEO and CFO concluded that disclosure controls and procedures were not effective because of material weaknesses in internal control over financial reporting identified in the December 31, 2025 Form 10-K.
- Immediate Nasdaq delisting risk
- Nasdaq notified the company on July 10, 2026 that its closing bid price had been below $1.00 for 30 consecutive business days, from May 26 through July 8, 2026. The company was deemed ineligible for the usual 180-calendar-day compliance period because it had effected a 1-for-10 reverse stock split on August 12, 2025.
- EnVue transaction may trigger delisting
- Nasdaq stated that the EnVue transaction involved 1,734,995 common shares and 57,720 Series X preferred shares convertible into 57,720,000 common shares, and could constitute a change of control requiring initial-listing compliance. The company has not satisfied those initial listing requirements since closing, and Nasdaq could immediately delist the stock if it concludes the transaction violated Listing Rule 5110(a).
What they said about what is next.
The provided 10-Q text does not include quantitative revenue or EPS guidance. No forward operating outlook was identified.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 18, 2026
- ENvue Medical's Q4 results for 2026 show a significant revenue decline of 36% to $653,000 due to issues related to product removals, exacerbated by high operational costs leading to an increased net loss of $3.8…
- 10-K · April 15, 2026
- ENvue Medical (formerly NanoVibronix) is transitioning after a 2025 merger into a two-pronged medical device company (Nano OpCo and ENvue) with a strategy to commercialize an electromagnetic navigation platform (ENvue…
- 10-Q · November 14, 2025
- Q3 2025 showed revenue growth but heavy operating spending and a continued cash burn. Revenue rose to $722,000 (Q3 2025) from $376,000 (Q3 2024), but operating loss widened to $(2,247,000) and the company used…
- 10-Q · November 14, 2024
- NanoVibronix reported quarterly revenue of $376,000 (Q3 2024) down from $458,000 in Q3 2023, but year-to-date revenue improved to $2,114,000 vs $1,106,000 a year earlier. The company remains loss-making (net loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FEED makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever